Results 11 to 20 of about 389,573 (268)

New vaccine development [PDF]

BMJ, 2002
Vaccines are hailed as one of the most important public health achievements of the 20th century.1 In the next five to 15 years, new vaccines and new vaccine delivery technology will fundamentally change how clinicians prevent and treat disease, with a substantial impact on public health.
Gregory A, Poland, Dennis, Murray, Ruben, Bonilla-Guerrero   +2 more
openaire   +2 more sources

Performance of a Four-Antigen Staphylococcus aureus Vaccine in Preclinical Models of Invasive S. aureus Disease

Microorganisms, 2021
A Staphylococcus aureus four-antigen vaccine (SA4Ag) was designed for the prevention of invasive disease in surgical patients. The vaccine is composed of capsular polysaccharide type 5 and type 8 CRM197 conjugates, a clumping factor A mutant (Y338A-ClfA)
Ingrid L. Scully, Yekaterina Timofeyeva, Arthur Illenberger, Peimin Lu, Paul A. Liberator, Kathrin U. Jansen, Annaliesa S. Anderson   +6 more
doaj   +1 more source

Meningococcal serogroup B vaccines: Estimating breadth of coverage

Human Vaccines & Immunotherapeutics, 2017
Neisseria meningitidis serogroup B (MenB) is an important cause of invasive meningococcal disease. The development of safe and effective vaccines with activity across the diversity of MenB strains has been challenging.
Robert G. K. Donald, Julio Cesar Hawkins, Li Hao, Paul Liberator, Thomas R. Jones, Shannon L. Harris, John L. Perez, Joseph J. Eiden, Kathrin U. Jansen, Annaliesa S. Anderson   +9 more
doaj   +1 more source

Neutrophil killing of Staphylococcus aureus in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study

Diabetology & Metabolic Syndrome, 2017
Background Obesity, metabolic syndrome (MetS), and diabetes are frequent in surgical populations and can enhance susceptibility to postoperative surgical site infections.
Ingrid Lea Scully, Lisa Kristin McNeil, Sudam Pathirana, Christine Lee Singer, Yongdong Liu, Stanley Mullen, Douglas Girgenti, Alejandra Gurtman, Michael W. Pride, Kathrin Ute Jansen, Paul L. Huang, Annaliesa S. Anderson   +11 more
doaj   +1 more source

MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies

Infectious Diseases and Therapy, 2020
Introduction Two phase 3 studies in adolescents and young adults demonstrated that MenB-FHbp, a meningococcal serogroup B (MenB) vaccine, elicits protective immune responses after 2 or 3 doses based on serum bactericidal antibody assays using human ...
Johannes Beeslaar, Judith Absalon, Annaliesa S. Anderson, Joseph J. Eiden, Paul Balmer, Shannon L. Harris, Thomas R. Jones, Robert E. O’Neill, Jean-Louis Pregaldien, David Radley, Roger Maansson, John Ginis, Amit Srivastava, John L. Perez   +13 more
doaj   +1 more source

Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults

Human Vaccines & Immunotherapeutics, 2018
A novel Staphylococcus aureus 4-antigen vaccine (SA4Ag) is under development, comprising capsular polysaccharide serotypes 5 and 8 (CP5 and CP8) conjugated to CRM197, recombinant protein clumping factor A (rmClfA), and recombinant manganese transporter ...
Megumi Inoue, Takuma Yonemura, James Baber, Yasuko Shoji, Masakazu Aizawa, David Cooper, Joseph Eiden, William C. Gruber, Kathrin U. Jansen, Annaliesa S. Anderson, Alejandra Gurtman   +10 more
doaj   +1 more source

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data

Infectious Diseases and Therapy, 2020
Introduction An extensive clinical development program showed that the meningococcal serogroup B-factor H binding protein (MenB-FHbp) vaccine affords protection against MenB disease for adolescents and adults.
Johannes Beeslaar, Paula Peyrani, Judith Absalon, Jason Maguire, Joseph Eiden, Paul Balmer, Roger Maansson, John L. Perez   +7 more
doaj   +1 more source

Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine

Nature Communications, 2022
In this phase 2 clinical trial, the authors assess protective efficacy of a Plasmodium vivax circumsporozoite vaccine in naïve and semi-immune individuals from controlled human malaria infection as well as antibody and IFN-γ response to vaccination.
Myriam Arévalo-Herrera, Xiomara Gaitán, Michelle Larmat-Delgado, María Alejandra Caicedo, Sonia M. Herrera, Juliana Henao-Giraldo, Angélica Castellanos, Jean-Christophe Devaud, André Pannatier, José Oñate, Giampietro Corradin, Sócrates Herrera   +11 more
doaj   +1 more source

A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2

Vaccines, 2023
(1) Background: We previously reported the development of a recombinant protein SARS-CoV-2 vaccine, consisting of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, adjuvanted with aluminum hydroxide (alum) and CpG oligonucleotides.
Syamala Rani Thimmiraju, Rakesh Adhikari, Maria Jose Villar, Jungsoon Lee, Zhuyun Liu, Rakhi Kundu, Yi-Lin Chen, Suman Sharma, Karm Ghei, Brian Keegan, Leroy Versteeg, Portia M. Gillespie, Allan Ciciriello, Nelufa Y. Islam, Cristina Poveda, Nestor Uzcategui, Wen-Hsiang Chen, Jason T. Kimata, Bin Zhan, Ulrich Strych, Maria Elena Bottazzi, Peter J. Hotez, Jeroen Pollet   +22 more
doaj   +1 more source

Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

Human Vaccines & Immunotherapeutics, 2017
A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of the vaccine is to significantly reduce the parasite burden of Trypanosoma cruzi in humans, either as a ...
Christopher A. Seid, Kathryn M. Jones, Jeroen Pollet, Brian Keegan, Elissa Hudspeth, Molly Hammond, Junfei Wei, C. Patrick McAtee, Leroy Versteeg, Amanda Gutierrez, Zhuyun Liu, Bin Zhan, Jonathan L. Respress, Ulrich Strych, Maria Elena Bottazzi, Peter J. Hotez   +15 more
doaj   +1 more source